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Abstract 
Objectives: To formulate chitosan nanoparticles with specific combinations of molecular weight and 
degree of deacetylation (DDA) that could be developed into an oral insulin delivery system. 
Methods: This study was conducted at Jordanian Pharmaceutical Manufacturing Company (JPM), 
Jordan in the period 2006-2009. 
Nanoparticles were prepared by polyelectrolyte complexation method (PEC). The physicochemical 
characteristics of the nanoparticles were evaluated. The role of nanoparticles in stabilization of insulin 
at high temperature and protecting insulin from pancreatic degradation was investigated.  
Results: The PEC formation process is influenced by a variety of parameters, including the system 
pH, chitosan molecular weight and DDA. The most important factor appears to be the system pH. 
All insulin-chitosan complexes displayed positive zeta potential. PECs protect insulin from 
pancreatin and the protective ability affected by DDA of chitosan. The results of insulin stability 
indicate that insulin-chitosan PEC protects insulin from degradation for at least 24 h. 
Conclusions: Molecular parameters of chitosan nanoparticles play an important role in stabilization 
of insulin in the GIT. So we can modulate relative parameters to develop an oral insulin delivery 
system. 
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ecently, nanoparticles have 
increasingly been investigated as 
carriers for hydrophilic 
macromolecular drugs such as peptides, 
proteins, vaccine and DNA to improve 
stability and permit administration through 
non-parenteral routes1-3.
Many different hydrophilic nanoparticles 
have been developed as drug carriers to take 
advantage of the hydrophilic properties of 
proteins and peptides. Chitosan a hydrophilic 
polysaccharide is characterized for its 
biodegradable, biocompatible, permeation 
enhancing effect, and mucoadhesive 
properties providing several pharmaceutical 
applications4-6.
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 Different methods have been used to prepare 
chitosan nanoparticles. These include 
emulsion cross-linking, 
coacervation/precipitation, spray drying, 
emulsion coalescence method, reverse 
micellar method, and ionic gelation7.
Previously described insulin-loaded chitosan 
nanoparticles were prepared by ionotropic 
gelation of chitosan with tripolyphosphate 
anions8, 9. Recently, polyelectrolyte 
complexation method was utilized to prepare 
insulin- trimethyl chitosan nanoparticles for 
intranasal delivery of insulin10.
With regard to chitosan-based PEC, nearly all 
insulin-loaded PEC have been prepared using 
high molecular weight chitosans or chitosan 
derivatives.  Chitosan is a polycation with an 
apparent pka 6; hence, in neutral and basic 
environments prevailing in the intestine, the 
chitosan molecules lose their charge and 
precipitated11 However, the solubility of 
chitosan increased with decreasing molecular 
weight. In addition, Low molecular weight 
R
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chitosans (LMWCs) with high degree of 
deacetylation possess high reactivity due to a 
greater number of amino groups available for 
interactions with the anionic actives12.
Moreover, their intestinal absorption is known 
to be significantly better than the high 
molecular weight candidates and showed 
negligible cytotoxic effect on the Caco-2 
cells13.
Hence the main aim of this work was to 
formulate LMWC nanoparticles with specific 
combinations of molecular weight and degree of 
deacetylation that could be developed into an 
oral insulin delivery system. Initially, insulin-
chitosan PECs were prepared. The 
physicochemical characteristics of the 
nanoparticles were evaluated. In addition, the 
influence of both molecular weight (M.wt), in 
the low range, and DDA of chitosan on 
nanoparticle properties and insulin stability 
were studied simultaneously. Furthermore, 
the role of chitosan in protecting insulin from 
pancreatic degradation was also investigated.  
Materials and Methods 
Materials 
Two chitosan grades were used in the study: 
the commercial low molecular weight 
chitosan (LMWC) molecular weight < 5 KDa 
and degree of deacetylation DDA of 81%, 
Shanghai Nicechem Co, China, b) molecular 
weight < 10 KDa and DDA of 80%, Shanghai 
Nicechem Co, China, and c) molecular weight 
< 50 KDa and DDA of 82%, Shanghai 
Nicechem Co, China and high molecular 
weight chitosan (HMWC) MWT >250 KDa 
and DDA 95%, Xiamen Xing, China. 
Pancreatin (activity equivalent to 4x USP, lot 
No.044 k1660) was purchased from Sigma-
Aldrrich, Germany.  
Methods 
Preparation and characterization of low 
molecular weight chitosan (LMWC) 
 Depolymerization of high molecular weight 
chitosan.  
Ten grams of the high molecular weight 
chitosan were dissolved in 1 L of 2 M HCl. 
The solution was heated for 3.5 h under 
reflux. After cooling, 3 L of ethanol (96%) 
was added and the precipitate was washed 
thoroughly with ethanol and freeze dried for 
24 h. The resultant chitosan powder was 
identified by Fourier transform infrared 
(FTIR) spectroscopy. 
Determination of molecular weight. 
The viscosity of chitosan hydrochloride 
dissolved in water was measured using a 
viscometer (Vibro viscometer, SV-10, Japan), 
and the viscosity average molecular weight 
was deduced using the Mark–Houwink’s 
equation, (η) = K (Mv)a where (η) is the 
intrinsic viscosity, M is the viscosity average 
molecular weight, and k and a values were 
0.00058 and 0.69 based on a previous study14.
Determination of degree of deacetylation.  
The degree of deacetylation (DDA) was 
determined according to spectroscopic 
method of the British Pharmacopoeia (B.P) 
2007. 
 
Preparation and characterization of 
insulin–chitosan polyelectrolyte complex 
(PEC) 
Insulin–chitosan complex preparation.
Chitosan with volume of 0.5 g was placed in a 
glass vial,  dissolved in 10 mL deionized 
water and its pH was adjusted to 5.5 using 
about 4 mL of 0.2 M NaOH, and the final 
volume was completed to 20 mL using 
deionized water. In another vial, 100 mg of 
rh-insulin powder was dissolved in 1 mL of 
0.1 M HCl, followed by the addition of 3 mL 
of 1 M tris (hydroxymethyl)-aminomethane 
buffer pH 7. Equal volumes of the chitosan 
and insulin were stirred gently using magnetic 
stirrer for 15 min at 4 °C. 
.Insulin–chitosan association efficiency (AE).  
To determine the association efficiency of 
insulin with chitosan, triplicate batches of 
insulin–chitosan polyelectrolyte complex 
were centrifuged at 15000 rpm for 30 min at 
15 °C and the insulin content in the 
supernatant was assayed by reversed phase 
high pressure liquid chromatography (RP-
HPLC) as mentioned earlier15. The 
association efficiency was calculated as 
described elsewhere16 using the following 
equation: 
Association efficiency = 
Total amount of insulin-Free insulin   X 100% 
Total amount of insulin 
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The factors that might affect the AE, were 
studied, namely, final pH of the complex (6.5 
or 6.8), molecular weight of chitosan (2.3, 3, 
13 or 30 KDa), DDA of chitosan (80 or 
100%),   and chitosan: insulin ratio (1:1, 2:1 
or 3:1). 
Determination of particle size and zeta 
potential of insulin–chitosan complex 
The particle size distribution of nanoparticles 
was carried out with Zetasizer Nano-ZS 
(Malvern Instruments, UK) at 25 ºC. 
Scattering light was detected at 173º angle. 
For data analysis, the viscosity (0.88 mPa.s) 
and the refractive index (1.33) of pure water 
at 25 °C were used. 
The zeta potential measurements were 
acquired using Zetasizer Nano ZS at 25 °C. 
Samples of free chitosan and insulin–chitosan 
PEC were measured in folded capillary cells 
integrated with gold electrodes. Three 
measurements were conducted, and the 
number of runs in each measurement was 
automatically determined by the software. 
Smoluchowski approximation was used and 
the results were expressed as mean ± SD. The 
viscosities of samples were measured by Sine 
wave Vibro viscometer (SV-10, A&D 
Company, Japan) at 25 °C ± 0.01 in triplicate. 
 
Effect of temperature on insulin stability 
Determination of melting temperature of 
insulin.
Melting temperature measurements were 
carried out with Zetasizer Nano ZS using a 1 
°C incremental temperature ramp and a 3 min 
equilibrium time at each melting temperature 
measurement. Insulin solutions in tris buffer 
with the concentration of 1 mg/mL and pH 7 
± 0.1 were prepared and their melting 
temperature was determined. The marked 
point where both the size and the intensity 
start to increase significantly is called melting 
temperature (Tm). 
Effect of temperature on the stability of 
insulin–chitosan PEC. 
 To evaluate the effect of LMWC on the 
stability of insulin, accelerated stability 
testing was conducted. PEC suspension with 
volume of 10 mL was prepared as mentioned 
above except that the final concentration of 
both insulin and chitosan was adjusted to 500 
lg/mL. PEC suspension was incubated in a 
water bath shaker at 55 ± 1 °C with shaking 
of 100 strokes/min. At predetermined time 
points (0, 12, 24, 48 h), aliquots were 
withdrawn and diluted with 0.01 M HCl to 
dissolve the nanoparticles. The insulin content 
was determined by RP-HPLC as described 
earlier. In addition, the stability of a standard 
insulin solution was assessed under the same 
testing conditions. All samples were prepared 
in triplicate. 
 
Enzymatic stability studies with pancreatin  
In order to investigate the role of chitosan in 
protecting insulin from pancreatic 
degradation, insulin-chitosan complexes were 
prepared from chitosans of different 
molecular weight and degree of deacetylation. 
1 ml of the complex or free insulin was 
incubated with 4 ml of SIF with pancreatin 
according to USP 2007 at 37 °C while 
shaking at 100strokes/min. Aliquot volume of 
100 µl was taken after 1 hr and samples were 
diluted with 0.01M HCl to terminate the 
pancreatic action and analyzed by RP-HPLC. 
The average and standard deviation of three 
replicates were calculated. 
 
Results and discussion 
 
Depolymerization, molecular weight and 
degree of deacetylation determination 
Depolymerization of high molecular weight 
chitosan by hydrochloric acid was carried out 
according to previously reported methods17, 
18. This yielded fractions of low molecular 
weight chitosans. Identification of these 
fractions was carried out by FTIR which 
showed similar distinct peaks as appeared in 
the parent compound. This  evidenced that 
depolymerization process did not change the 
basic chemical structure. 
The degree of deacetylation of depolymerized 
and commercial chitosans was determined by 
first derivative spectroscopic (FDUV) 
method. As shown in Table 1 DDA of 
depolymerized fractions were around 100% 
which indicated that the samples were 
completely deacetylated.
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Table 1. Degree of deacetylation of chitosans 
 
Chitosan M. wt 
(KDa) 
Source DDA calculated by 
FDUV method 
DDA calculated by 
NMR method 
3 Depolymerized 99.80 ± 0.05 100 
13 Depolymerized 99.90 ± 0.38 100 
28 Depolymerized 99.00 ± 0.71 100 
2.3 Commercial 84.28 ± 0.42 83.33 
8 Commercial 83.00 ± 0.63 82 
30 Commercial 82.48 ± 0.31 78.74 
The high values obtained were in an 
agreement of a previous report19. There is 
slight increase in the degree of deacetylation 
of depolymerized LMWC when compared to 
the native high molecular weight chitosan 
(DDA 93%), indicating that hydrochloric acid 
can hydrolyzed O-glycosidic linkages 
(depolymerization) as well as the -acetyl 
linkage (de-N-acetylation) though at different 
rates20.
Preparation of insulin–chitosan PEC 
Insulin and chitosan mixture was prepared 
through the gradual addition of the two 
solutions containing materials with opposite 
charges to facilitate the formation of the PEC. 
However, PEC preparation was previously 
reported for polymers having ionizable 
groups and bear opposite charges21.
Insulin–chitosan PEC association efficiency 
Effect of pH on AE.  
Chitosan having low molecular weight and 
high degree of deacetylation is highly active 
due to a greater number of amino groups 
available for interactions with the anionic 
active sites12. Chitosan solution pH was 
adjusted to 5.5. At this pH about 90% of the 
amine groups are protonated as it has an 
apparent pKa of ~6.511. Such protonation 
leads to chain repulsion and more extended 
conformations22. This exposes the amine 
groups to the negatively charged insulin 
leading to their interaction. Insulin has an 
apparent isoelectric point (pI) of 6.4 and a 
charge of -2 at a final pH of ~6.823. The 
influence of the final pH on association 
efficiency was evaluated as presented in 
Table 2. 
 
Table 2: Effect of pH and insulin to chitosan 
weight ratio on AE (average ± standard 
deviation), n = 3 
 
pH AE ± SD 
6.5 78.81 ± 0.68
6.8 30.38 ± 3.71
Ratio (w/w) AE ± SD 
1:1 78.81 ± 0.68
1:2 73.38 ± 3.42
1:3 77.11 ± 3.94
*Chitosan 13 KDa, DDA = 99.9 
High AE was obtained at pH 6.5 (about 80%). 
It was reported that the formation of PEC 
between the two oppositely charged polymers 
can only occur at pH values in the vicinity of 
the pKa interval of the two polymers21. The 
AE fell sharply when the final pH of the 
complex was adjusted to 6.8 (about 30%). 
This finding is in agreement with studies of 
Ma et al24 who recorded a sharp change in AE 
with small pH changes. It seems that chitosan 
becomes increasingly globular as the pH 
increases, and starts to precipitate22.
Effect of molecular weight and DDA 
It is expected that the spread length of 
chitosan chain in solution may vary in  
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correlation with the molecular weight, which 
may affect protein interaction and 
encapsulation. Longer chains may offer more 
reactive sites for the formation of hydrogen 
bonds with protein molecules, especially if a 
protein maintains a compact structure and not 
fully extended at the solution conditions25.
On the other hand, It is expected that shorter  
chains have greater flexibility and therefore 
more preferable for interaction12.
The effect of chitosan molecular weight on 
the AE was evaluated (Figure 1). Low 
association efficiency for the shorter chain 
chitosans (2.3 and 3 KDa) was observed. 
Optimum polymer /insulin (+/-) charge ratio 
was essential for PEC formation26.
Figure 1. Effect of M.wt and DDA of chitosan on the association efficiency of insulin 
 
The same weight ratio (1 to 1chitosan to 
insulin) was used in this comparative study, 
the decrease in AE for chitosans (2.3 and 3 
KD) could be attributed to lower charge 
densities on shorter chain chitosans compared 
to the other chitosans. For example zeta 
potential for chitosan 2.3 and 30 KDa was 
+13.71 and +27.87 respectively.  
AE was also affected by the DDA of chitosan, 
as the DDA increases the encapsulation 
increases as well (Figure1). This is to be 
expected as higher DDA may offer more 
reactive sites for electrostatic interaction with 
insulin 
Effect of chitosan to insulin ratio on AE.  
The AE was not affected when chitosan to 
insulin ratio was increased from 1: 1 to 3:1 as 
shown in Table 2. This finding is inconsistent  
 
with some previous studies27, 28. This 
contradiction may be attributed to the 
differences in the chitosan molecular weight 
used and their purity. Chitosan /insulin charge 
ratio (+/_) was calculated according to the 
charge and  pKa of the components at pH 6.5. 
It was found 9:1 and 27:1 for chitosan/insulin, 
1:1 and 3:1 w/w ratio, respectively. The 
positive charge of chitosan was present in 
molar excess, and may partially explain the 
constant AE at different chitosan to insulin 
ratios. 
However, it is not only the charge but 
chitosan conformation and viscosity were also 
known to be affected upon the increase in 
chitosan concentration in solution state. All of 
these factors could influence the interaction of 
chitosan and insulin and, hence, affecting the 
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AE. It was reported that chitosan at high 
concentration adopts a random coil 
conformation, and the proportions of the 
charged segments are shielded due to strong 
intermolecular interactions29. In addition, the 
viscosity of chitosan increases with the 
increase in chitosan concentration in 
solution22. This may hamper the kinetics and 
led to a limited binding with insulin. 
 
Particle size and Zeta potential.
An increase in the molecular weight of the 
chitosan polymer led to an increase in the 
dispersed phase particle size as shown in 
Table 3. This finding is in agreement with 
other published studies10.
As expected the zeta potential of chitosan is 
positive due to presence of amino groups. All 
chitosan–insulin complexes displayed a lower 
positive zeta potential in comparison with the 
free chitosan. The ratio of negative charge 
(insulin) to the positive charge of the chitosan 
remains in the favor of the positive charge of 
the polymer as only a fraction is neutralized 
by binding insulin. This indicated that partial 
neutralization of chitosan charge took place. 
These results agree well with the results 
reported by Sadeghi et al16.
Table 3. Particle size and Zeta potential of free chitosan and chitosan-insulin PEC prepared from 




DDA (%) ± SD 
 
Particle Size ± SD 
Zeta Potential  (mv) ± SD 
Free Chitosan Chitosan-Insulin 
2.3 81 ± 0.42 63 ± 4.0 13.17 ± 1.41 7.93 ± 0.48
30 82 ± 0.31 141 ± 15.6 27.87 ± 0.45 12.30 ± 1.47
3 100.8 ± 0.04 79 ± 2.5 27.6 ± 0.62 7.07 ± 0.29 
13 99.9 ± 0.38 111 ± 6.9 56.83 ± 0.31 19.97 ± 1.65
30 100 ± 0.71 205 ± 2.6 51.7 ± 2.18 21.77± 1.15 
Insulin stability 
Insulin is a labile protein similar to other 
proteins. They are affected by formulation 
components, process and storage 
temperature30. It is well established that all 
proteins unfold above their melting 
temperature Tm30. In order to assess insulin 
stability the temperature used for testing 
should be far enough from its Tm. 
Consequently, Tm of insulin should be first 
measured prior to accelerated stability testing. 
Melting point of insulin in tris buffer 
Different techniques have been used to 
determine Tm, such as differential scanning 
calorimetry, infrared spectroscopy and 
capillary electrophoresis 31 ,32.
Figure 2. Melting temperature of insulin dissolved in 0.5 M tris (hydroxymethyl)-aminomethane 
buffer. 
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Recently, dynamic light scattering technique 
(DLS) was used, when denaturation occurs, 
the small 
size of the protein is increased to a value 
consistent with a random coil polymer of the 
same molecular weight. In the absence of 
chaotropic (aggregation prohibiting) agents, 
inter-polymer hydrophobic interactions may 
quickly lead to non-specific aggregation of 
the denatured polypeptide chains. The change 
in size that accompanies the protein 
denaturation is easily identified using DLS. 
Figure 2 shows the melting temperature 
profile for insulin dissolved in tris buffer. At 
temperatures less than 60 °C, the size and 
scattering intensity are constant, suggesting a 
stable tertiary structure. At temperatures 
higher than 61 °C, both the size and scattering 
intensity increase exponentially with 
temperature, indicating the presence of 
denatured aggregates. The Tm determined by 
DLS is in agreement with that reported in 
literature using DSC technique33. The average 
Tm of insulin obtained in this study was 63 ± 
1 °C. 
Accelerated stability of insulin–chitosan PEC 
To illustrate the role of LMWC on 
stabilization of insulin, insulin–chitosan PEC 
(Chitosan 13 KDa) was subjected to 55 °C 
temperature which is 8 °C less than the Tm of 
insulin and was compared with the free 
insulin solution. It is worth mentioning that 
other investigators used temperatures ≥40 °C
to study the stability of insulin preparations34.
After 48 h insulin solution was almost 
completely degraded as shown in Figure 3.
Figure 3. Stability of free insulin and insulin-chitosan PEC placed on a water bath shaker at a 
temperature of 55 °C with 100 strokes/min. 
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High temperature causes denaturation of 
insulin by the rapid formation of bovine 
insulin fibrils30. In addition, high temperature 
accelerates its chemical degradation. It was 
reported that formation of insulin oligomers 
and polymers increases at temperature ≥25
°C35, while shaking creates hydrophobic 
air/water interface and, therefore, initiate 
aggregation36. However, insulin–chitosan 
PEC protects insulin from degradation for at 
least 24 h. Although high molecular weight 
chitosan and chitosan derivatives were found 
to enhance the thermal stability of insulin37,
the effect of chitosan low molecular weight 
has yet to be investigated. The protective 
effect of PEC may be due to the reduction of 
aggregation and fibrillation of insulin as free 
insulin solution becomes turbid after 24 h. 
Other cationic polymers such as poly 
(ethylene glycol)-b-poly (L-histidine) that 
forms PEC with insulin reduce aggregation of 
insulin on agitation38. Consequently, one can 
assume that LMWC reduces insulin 
aggregations. In addition, Mao et al. 
suggested that higher temperature causes 
compaction of insulin nanoparticles10.
However, the influence of LMWC is still 
wide open for investigation. 
 
Stability of insulin-chitosan (Ins-Cs) complex 
in simulated intestinal fluid (SIF) 
 
The potential role of chitosan in protecting 
insulin from enzymes present in the small 
intestine was evaluated. The enzymatic 
stability of insulin was investigated in the 
presence of pancreatin. Figure 4 depicts the 
percentage of undegraded insulin after 
incubation of insulin-chitosan PECs (1 to 1 
ratio) prepared from chitosans of different 
molecular weight and degree of deacetylation 
with pancreatin for 1 hr and compared to free 
insulin solution. 
 
Figure 4. Enzymetic degradation of insulin by pancreatin (USP 2007). Each value represents the 
mean ± S.D. n =3. 
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Partial protection of insulin from pancreatin 
was observed with chitosans of 100% DDA 
(P < 0.05) with relatively similar values 
(about 60%) for the M.wt. 3, 13 and 28 KDa, 
whereas, lower protection was manifested for 
chitosans with DDA 80%. The higher M.wt 
30 KDa displayed significant protection 
compared to free insulin (P < 0.05) in contrast 
the lower molecular weight 2.3 KDa did not 
protect insulin from pancreatic digestion 
under similar conditions (P > 0.05). The 
significant difference in enzymatic protection 
of insulin between chitosans with DDA 100% 
and DDA 80% (P < 0.05) could be attributed 
to the higher percentage of encapsulated 
insulin in the case of chitosans with DDA 
100%.
Another experiment was conducted to 
evaluate the effect of increasing chitosan to 
insulin ratio on enzymatic protection. PECs 
composed of chitosan (13 KDA, DDA, 99%) 
to insulin ratios 3 to 1, 2 to 1 and 1 to 1 were 
prepared and compared with free insulin 
solution as shown in Figure 5.  
Figure 5. Effect of chitosan:Insulin ratio on pancreatic degradation of insulin 
 
A pronounced enzymatic protective effect of 
PECs was noted compared to free insulin 
solution (P < 0.05). The protection increases 
with increasing chitosan ratio. A significant 
difference between chitosan-insulin ratios 3 to 
1 and 1 to 1 (P < 0.05) was observed at all 
time intervals. As discussed earlier there is no 
significant difference in the encapsulation 
efficiency between different ratios. The 
significant difference in enzymatic protection 
could be due to excess positive charge of the 
higher ratio leading to repulsion of trypsin as 
it is also positively charged39. Another 
possible explanation is that phosphate ions of 
phosphate buffer could bind to the positively 
polymer and form a gel layer that hinder the 
penetration of the enzyme. As the ratio of 
chitosan increases, the thickness of this layer 




Insulin-chitosan PECs were prepared using 
LMWT chitosans. Nanoparticles with specific 
combinations of molecular weight and degree of 
deacetylation were dispersed in an oily vehicle 
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and an oral insulin delivery system was 
developed by our group. In vivo tests were 
conducted both on animals and humans40, 41.
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